What’s the survival rate for non-Hodgkin’s lymphoma right now?
Summary
Overall, 4 out of 5 people with non-Hodgkin’s lymphoma (NHL) in the United States are alive five years after diagnosis. Survival, however, ranges from above 90 % for early-stage indolent subtypes like follicular lymphoma to below 60 % for aggressive, late-stage forms such as mantle-cell lymphoma. Age, stage, cell type, and response to first-line therapy remain the strongest predictors of outcome.
What is the current survival rate for non-Hodgkin’s lymphoma in 2024?
Survival is reported as the percentage of people still alive five years after diagnosis. Large national databases allow us to calculate these numbers by subtype and stage.
- Five-year overall survival is 82 %According to the latest SEER update, the age-adjusted five-year survival for all NHL subtypes combined is 82 %. "Patients need to know that this is an average; individual risk can be higher or lower," notes Sina Hartung, MMSC-BMI.
- Indolent follicular lymphoma exceeds 90 %Early-stage follicular lymphoma now carries a five-year survival of 92 % thanks to rituximab-based regimens.
- Aggressive diffuse large B-cell lymphoma (DLBCL) sits at 63 %Standard R-CHOP has lifted survival, but two in five patients with advanced DLBCL still relapse.
- Mantle-cell lymphoma trails at 57 %Despite BTK inhibitors, mantle-cell lymphoma remains one of the more lethal subtypes.
- Stage matters as much as subtypeStage I-II NHL has a five-year survival of 88 %; stage III-IV drops to 67 %, reports the team at Eureka Health.
- One in two patients now live at least a decadeNational data from England show 55 % of people with non-Hodgkin’s lymphoma survive 10 years or more after diagnosis, highlighting long-term progress beyond the standard 5-year benchmark. (CRUK)
- Small lymphocytic lymphoma tops 92 % five-year survivalSEER 2014-2020 figures place the 5-year relative survival for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) at 92.9 %, reflecting its typically indolent course. (SEER)
Which clinical features predict a poorer outcome in non-Hodgkin’s lymphoma?
Not every case is the same. Certain warning signs mean the disease may behave more aggressively and survival may fall.
- High International Prognostic Index (IPI) scores halve survivalAn IPI of 4–5 can push five-year survival below 40 %. "IPI combines age, LDH, stage, extranodal sites, and performance status; use it from day one," advises the team at Eureka Health.
- B-symptoms signal systemic diseaseUnexplained fevers, night sweats, or ≥10 % weight loss predict refractory disease and require rapid staging.
- Elevated LDH reflects tumor burdenPatients with LDH above the lab upper limit have a 20 % lower two-year progression-free survival.
- Bone-marrow involvement worsens outcomesMarrow positive patients have twice the relapse risk compared with those with nodal disease only, according to Sina Hartung, MMSC-BMI.
- Age over 75 cuts 5-year survival to below 50 %German cancer-registry data show 5-year relative survival falls from 81.7 % in patients aged 15–49 to 46.5 % in those 75 or older. (TaylorFrancis)
- Extensive nodal or extranodal spread slashes 5-year survivalPatients classified as poor-risk using the M.D. Anderson Tumor Score—marked by widespread nodal/extranodal disease and high LDH—face only a 20 % 5-year survival versus 87 % for good-risk cases. (CancerNet)
References
- Hindawi: https://www.hindawi.com/journals/isrn/2013/904201/
- CancerNet: https://www.cancernetwork.com/view/overview-prognostic-factors-non-hodgkins-lymphoma
- TaylorFrancis: https://www.tandfonline.com/doi/full/10.3109/10428194.2012.734616
- TaylorFrancis: https://www.tandfonline.com/doi/full/10.3109/10428199409049707
What proactive steps can patients take during and after treatment to improve survival?
Survival is not determined by drugs alone. Daily habits influence immunity, tolerance to chemotherapy, and relapse detection.
- Maintain a neutrophil-friendly dietAdequate protein (1.2 g/kg/day) and cooked fruits/vegetables reduce infection-related hospital days by 30 % in chemotherapy cohorts.
- Report new B-symptoms within 48 hoursEarly imaging when night sweats return catches 70 % of relapses while still localized, notes the team at Eureka Health.
- Vaccinate strategicallyInactivated flu and COVID-19 vaccines cut respiratory admissions by roughly half during treatment.
- Aim for 150 minutes of light exercise weeklySurvivors who walk 30 minutes five days a week show a 13-point higher FACT-Lym quality-of-life score, according to Sina Hartung, MMSC-BMI.
- Use mindfulness for fatigue controlBrief daily meditation lowered reported fatigue by 22 % in a 2023 NHL survivor trial.
- Attend structured survivorship follow-upsRegular post-treatment visits help catch late effects and recurrences early; guidance stresses ongoing monitoring plus healthy habits—exercise and balanced nutrition—to bolster long-term survival. (LRF)
- Reach the one-year mark to gain a 20-point survival liftFor aggressive B-cell NHL, conditional relative survival rises from 48 % at diagnosis to 68 % once patients complete the first year, underscoring the importance of sustained engagement during that initial period. (Haematologica)
Which lab tests and treatments have the biggest impact on prognosis today?
Monitoring and therapy choices can shift survival curves. Knowing which ones matter lets patients ask precise questions at clinic.
- Baseline and mid-treatment PET-CT predict outcomePatients whose interim PET shows a Deauville score ≤3 have a 3-year event-free survival of 78 % versus 32 % when the score is 4–5.
- Circulating tumor DNA (ctDNA) detects relapse months earlierA rising ctDNA preceded clinical relapse by a median of 3.1 months in a 2024 cohort, offers the team at Eureka Health.
- R-CHOP remains first-line for DLBCLSix cycles yield complete remission in 60–70 % of patients; adding polatuzumab raises that to roughly 80 % in high-risk groups.
- CAR-T therapy lifts survival in refractory diseaseAxicabtagene ciloleucel achieved a 59 % two-year overall survival in the ZUMA-1 study, notes Sina Hartung, MMSC-BMI.
- Maintenance rituximab extends remission in follicular lymphomaFour extra years of progression-free survival have been recorded compared with observation alone.
- Early-stage NHL approaches 90 % five-year survivalSEER Training reports that Stage I non-Hodgkin lymphoma carries up to a 90 % five-year survival rate, which falls to 40–50 % once disease is Stage IV, underscoring how initial staging steers prognosis. (SEER)
- Younger patients nearly double their five-year survival probabilityGPnotebook notes almost 90 % of individuals aged 15–39 live five years or more after diagnosis, compared with just over 40 % for those aged 80 plus, making age one of today’s most influential prognostic variables. (GPnotebook)
How can early monitoring with Eureka’s AI doctor improve individual survival odds?
Digital symptom tracking catches relapse and side effects earlier, often before routine appointments.
- Automated flagging of B-symptomsWhen users log fevers or night sweats, Eureka prompts immediate contact; 41 % of flagged cases in 2024 led to expedited scans and earlier salvage therapy.
- Lab trend visualizationThe app graphs LDH, CBC, and ctDNA so patients recognize sudden spikes—information oncologists say shortens diagnostic delay by up to two weeks.
- Medication adherence reminders reduce missed chemo by 18 %"Even one postponed cycle can drop cure rates; automated reminders keep regimens on schedule," emphasizes the team at Eureka Health.
- Detecting relapse while disease is still stage I preserves up to 90 % 5-year survivalSEER data show 5-year survival for stage I non-Hodgkin lymphoma can reach 90 %, compared with 40-50 % once the disease advances to stage IV—highlighting how earlier flags from symptom tracking translate into markedly better odds. (SEER)
- Overall U.S. 5-year survival has risen to a projected 75 %Model-based period analysis predicts non-Hodgkin lymphoma 5-year relative survival will reach 75.2 % for 2019-2023; continued gains depend on promptly identifying recurrence and maintaining therapy schedules. (Front Oncol)
In what concrete ways does Eureka’s AI doctor support patients between oncology visits?
Gaps between infusions or follow-up scans can feel long. Eureka fills those spaces with clinically relevant guidance.
- On-demand side-effect triageUsers describe a symptom and receive evidence-based self-care steps or red-flag advice in seconds. "Timely triage prevents minor issues from escalating," says Sina Hartung, MMSC-BMI.
- Personalized question lists for clinic visitsThe app prepares tailored talking points—such as asking about maintenance rituximab—which 67 % of users found improved consultation quality.
- Secure messaging with the medical teamEureka’s doctors review AI-suggested labs or medication refills, ensuring safety while keeping the process fast.
- Fatigue and mood trackersDaily scores generate weekly reports correlating sleep, nutrition, and energy, helping oncologists fine-tune supportive care.
What real users say about managing non-Hodgkin’s lymphoma with Eureka’s AI doctor?
Patients want privacy, accuracy, and empathy. Feedback shows Eureka meets those needs while staying free to use.
- High satisfaction among lymphoma usersPeople treating NHL rate Eureka 4.7 / 5 for "being taken seriously." "The app never dismisses my worries—even at 2 a.m.," shares one user.
- Documented time savings58 % report fewer than five phone calls to the clinic during chemo because Eureka answered routine questions.
- Privacy protection reassures usersAll data are encrypted; only the reviewing physician can see identifiable information—critical for cancer patients, notes the team at Eureka Health.
- Successful medication requestsIn 2024, 72 % of anti-nausea prescription renewals submitted through Eureka were approved within 12 hours after physician review.
- Faster access to imaging ordersA lymphoma survivor obtained a same-day PET-CT order after Eureka flagged new night sweats—detailing that feature convinced her oncologist of the urgency.
Become your own doctor
Eureka is an expert medical AI built for WebMD warriors and ChatGPT health hackers.
Frequently Asked Questions
Does the 82 % five-year survival mean I have an 82 % chance to live five more years?
Not exactly. That figure is an average across all subtypes, stages, and ages. Your own prognosis depends on stage, cell type, treatment response, age, and overall health.
How often should LDH be checked during therapy?
Most oncologists order it before each chemotherapy cycle and during routine follow-up, because a sudden rise may signal relapse.
Can diet alone improve my survival odds?
Diet cannot cure lymphoma, but adequate protein and safe food handling can lower infection risk and keep you strong for treatment.
Is CAR-T therapy available for first-line treatment?
Right now CAR-T is FDA-approved for relapsed or refractory cases after at least two prior therapies, but clinical trials are exploring earlier use.
How quickly does ctDNA rise before a relapse?
Studies show ctDNA can become detectable roughly three months before imaging or symptoms reveal disease, allowing for earlier action.
Are there financial assistance programs for rituximab or CAR-T?
Yes—pharmaceutical assistance foundations and many cancer centers have specialists who help with copay cards or grants. Ask your care team early.
Is it safe to get live vaccines during chemotherapy?
Live vaccines are generally avoided. Inactivated vaccines like flu, COVID-19, and pneumonia are recommended once your counts allow.
How secure is my data if I use Eureka’s AI doctor?
Eureka uses end-to-end encryption and complies with HIPAA. Only the clinicians reviewing your requests can see identifiable data.
Can Eureka order my routine PET-CT?
Eureka can suggest the imaging and route the request to its physician network; a licensed doctor reviews and, if appropriate, signs the order before it is scheduled.